

Published in final edited form as:

*Exp Parasitol.* 2015 January ; 0: 17–23. doi:10.1016/j.exppara.2014.11.004.

## Suppression of *Ov-grn-1* encoding granulin of *Opisthorchis viverrini* inhibits proliferation of biliary epithelial cells

Atiroch Papatpremsiri<sup>a,e</sup>, Michael J. Smout<sup>b</sup>, Alex Loukas<sup>b</sup>, Paul J. Brindley<sup>c</sup>, Banchob Sripa<sup>d</sup>, and Thewarach Laha<sup>e,f,\*</sup>

<sup>a</sup>Graduate School, Khon Kaen University, 40002 Khon Kaen, Thailand <sup>b</sup>Centre for Biodiscovery and Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, Queensland Tropical Health Alliance Laboratory, James Cook University, Cairns, Queensland 4878, Australia <sup>c</sup>Department of Microbiology, Immunology and Tropical Medicine, and Research Center for Neglected Diseases of Poverty, School of Medicine & Health Sciences, George Washington University, Washington, DC 20037, USA <sup>d</sup>Tropical Disease Research Laboratory, Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand <sup>e</sup>Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand <sup>f</sup>Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand

### Abstract

Multistep processes likely underlie cholangiocarcinogenesis induced by chronic infection with the fish-borne liver fluke, *Opisthorchis viverrini*. One process appears to be cellular proliferation of the host bile duct epithelia driven by excretory-secretory (ES) products of this pathogen. Specifically, the secreted growth factor *Ov*-GRN-1, a liver fluke granulin, is a prominent component of ES and a known driver of hyper-proliferation of cultured human and mouse cells *in vitro*. We show potent hyper-proliferation of human cholangiocytes induced by low nanomolar levels of recombinant *Ov*-GRN-1 and similar growth produced by low microgram concentrations of ES products and soluble lysates of the adult worm. To further explore the influence of *Ov*-GRN-1 on the flukes and the host cells, expression of *Ov-grn-1* was repressed using RNA interference. Expression of *Ov-grn-1* was suppressed by 95% by day 3 and by ~100% by day 7. Co-culture of *Ov-grn-1* suppressed flukes with human cholangiocyte (H-69) or human cholangiocarcinoma (KKU-M214) cell lines retarded cell hyper-proliferation by 25% and 92%, respectively. Intriguingly, flukes in which expression of *Ov-grn-1* was repressed were less viable in culture, suggesting that *Ov*-GRN-1 is an essential growth factor for survival of the adult stage of *O. viverrini* survival, at least *in vitro*. To summarize, specific knock down of *Ov-grn-1* reduced *in*

© 2014 Elsevier Inc. All rights reserved.

\***Corresponding author:** Thewarach Laha, Department of Parasitology, Faculty of Medicine, Khon Kaen University, 123 Mittraphap Highway, Khon Kaen 40002 Thailand; phone, +66 43 348387, thewa\_la@kku.ac.th.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

*vitro* survival and capacity of ES products to drive host cell proliferation. These findings may help to contribute to a deeper understanding of liver fluke induced cholangiocarcinogenesis.

## Keywords

*O. viverrini*; cholangiocarcinoma; RNA interference; granulins; liver fluke; cellular proliferation

## 1. Introduction

The International Agency for Research on Cancer recognizes infection with three helminth parasites as definitive causes of cancer as members of its Group 1 Carcinogens - the liver flukes *Opisthorchis viverrini* and *Clonorchis sinensis* and the blood fluke *Schistosoma haematobium* (Bouvard et al., 2009, de Martel et al., 2012, IARC, 2012). Liver fluke infection is of major public health concern in East Asia and Eastern Europe, where more than 40 million people are infected. *O. viverrini* infection is endemic in Thailand, Laos, Vietnam and Cambodia (Sithithaworn et al., 2012, Sripa et al., 2011). People acquire opisthorchiasis following ingestion of raw cyprinid fishes containing the metacercarial stage of *O. viverrini* (Sripa, 2012). Infected people may not exhibit clinical signs and symptoms; however, 5-10% of patients with chronic infection will progress to hepatobiliary disease including obstructive jaundice, hepatomegaly, cholecystitis, and/or cholangiocarcinoma (CCA) (bile duct cancer) (Smout et al., 2011, Sripa et al., 2012, Sripa et al., 2007). CCA is the eminent type of liver cancer in Thailand and Laos where consumption of uncooked fishes harboring the infectious larvae of this liver fluke is a dietary staple (Mairiang et al., 2012, Sripa and Pairojkul, 2008). Problematically, whereas the strong link between opisthorchiasis and CCA has been known for decades, the incidence of CCA remains high (Mairiang et al., 2012, Sripa et al., 2007). In resource limited settings such as rural Thailand and Laos, medical and surgical options are limited for CCA, and these options and care are complicated (Malhi and Gores, 2006, Razumilava and Gores, 2014).

Cancer of the bile ducts induced by infection with *O. viverrini* is thought to be a culmination of multi-factorial chronic inflammation and related disease processes (Plieskatt et al., 2013, Porta et al., 2011, Sripa et al., 2012). Of particular relevance to this study is the role of *O. viverrini* excretory-secretory products (ES) in establishing a carcinogenic microenvironment, including stimulating cellular proliferation of cholangiocytes lining the infected bile ducts (Smout et al., 2011, Sripa et al., 2007, Thuwajit et al., 2004). ES from *O. viverrini* stimulates the proliferation of both NIH-3T3 fibroblasts (Thuwajit et al., 2004) and the human KKU-100 cell line from a liver-fluke induced CCA (Smout et al., 2009). Using proteomic and transcriptomic approaches, *O. viverrini* ES and surface membrane proteins were characterized and shown to include a complex mixture of proteins, some of which have been associated with cancers, including proteases, protease inhibitors, orthologues of mammalian growth factors and anti-apoptotic proteins (Laha et al., 2007, Mulvenna et al., 2010). Of particular note was the identification of *Ov*-GRN-1, a protein with sequence similarity to the mammalian growth factor, granulins (Mulvenna et al., 2010, Smout et al., 2009). *Ov*-GRN-1 was expressed in diverse organs and tissues of the liver fluke, was detected on adjacent biliary epithelial cells of experimentally infected hamsters, and

antibodies raised to recombinant *Ov*-GRN-1 inhibited ES of *O. viverrini* from driving cellular proliferation (Smout et al., 2009). Hence it has become clear that *Ov*-GRN-1 is the major factor of ES, at large, that induces cell proliferation and, ultimately, likely promotes cholangiocarcinogenesis.

RNA interference (RNAi) is a natural mechanism involved with silencing the expression of genes to control homeostasis and other mechanisms (Shuey et al., 2002). This phenomenon has been co-opted in the laboratory in functional genomic approaches to analyze gene function in numerous eukaryotic species, including parasitic worms (Knox, 2012). Indeed, we successfully deployed RNAi to investigate genes in liver flukes (Rinaldi et al., 2008, Thanasuwan et al., 2014). It is notable, also, that suppression of human granulin-epithelin precursor by RNAi inhibits growth of hepatocellular carcinoma cells and shows promise as a treatment for this disease (Park et al., 2011). To further explore the role of *Ov*-GRN-1 in pathogenesis of opisthorchiasis, here we used RNAi to suppress the expression of *Ov-grn-1* in adult flukes, which lead to decreased viability of cultured flukes and compromised ability of ES to stimulate proliferation of cholangiocytes and related tumor cells.

## 2. Materials and methods

### 2.1. *Opisthorchis viverrini*

Metacercariae of *O. viverrini* were recovered from flesh of naturally infected fishes, as described (Laha et al., 2007, Sithithaworn et al., 1997). Syrian hamsters (*Mesocricetus auratus*) were infected with 50 metacercariae each via an intragastric tube (Sripa and Kaewkes, 2002). Hamsters were reared at the animal facility, Faculty of Medicine, Khon Kaen University. Study design protocols and standard operating procedures were approved by the Animal Ethics Committee of Khon Kaen University according to the Ethics of Animal Experimentation of the National Research Council of Thailand, approval number AEKKU43/2555. Hamsters were euthanized at six weeks after infection, at which point adult worms were recovered from the in gall bladders and bile ducts.

### 2.2. *O. viverrini* excretory-secretory products (ES) and lysate of adult worms

A soluble lysate of adult worms, which we termed somatic adult worm extract (SAE) was prepared from frozen and homogenized adult worms (Smout et al., 2009). ES was prepared from viable adult worms washed in antibiotics and incubated in modified RPMI-1640 (Life Technologies) at 37°C/5% CO<sub>2</sub> and the supernatant harvested daily for three days and stored at -80°C (Sripa and Kaewkes, 2000).

### 2.3. Recombinant protein production

Purification of *Ov*-GRN-1 recombinant protein was as our previously optimized protocol using BL21 *Escherichia coli* bacterial insoluble expression with refolding followed by pure monomer isolation (Smout et al., 2011).

### 2.4. Human cell culture

The non-malignant cholangiocyte cell line H69 is a SV40-transformed human bile duct epithelial cell line originally derived from a normal liver harvested for transplantation

(Grubman et al., 1994, Reid and Jefferson, 1984) and was obtained in 2010 from Dr. Gregory J. Gores, Mayo Clinic, Rochester, Minnesota. H69s were grown under similar conditions with growth factor supplemented specialized complete media (Matsumura et al., 2004); DMEM/F12 with high glucose, 10% fetal bovine serum (FBS), 1x antibiotic/antimycotic, 25 µg/ml adenine, 5 µg/ml insulin, 1 µg/ml epinephrine, 8.3 µg/ml holo-transferrin, 0.62 µg/ml, hydrocortisone, 13.6 ng/ml T3 and 10 ng/ml EGF (Life Technologies). H69 cells were grown in complete medium as described (Grubman et al., 1994). The KKKU-M214 cell line, derived from a moderately differentiated type human CCA was cultured in T75cm<sup>2</sup> vented monolayer flasks (Corning) in complete media [RPMI 1640 (Sigma) with 10% FBS and 1x antibiotic/antimycotic as previously described (Sripa et al., 2005).

Cell lines were incubated in 5% CO<sub>2</sub> at 37°C, and Trypan blue staining was used to determine cell viability. Cells were grown to ~80% confluence for further experiments. All growth assays for cells were performed in low nutrient media-5% complete media. For H69s this is 0.5% with FCS with 1/20<sup>th</sup> of the previously listed growth factors for complete media. For the KKKU-214 cell lines, this was RPMI 1640 medium with 0.5% with FCS.

## 2.5. Growth assays with xCELLigence

Cells were seeded at 3,000 cells/well in 200 µl of complete media (above) in E-plates (ACEA Biosciences, San Diego, California) and grown overnight while monitored with an xCELLigence SP system (ACEA Biosciences) which monitors cellular events in real time by measuring electrical impedance across inter-digitated gold micro-electrodes integrated on the bottom of tissue culture plates (Ke et al., 2011). Cells were washed three times with PBS and replaced with 180 µl of relevant low nutrient media and incubated for a minimum of six hours before further treatments. Treatments were prepared at 10× concentration in low nutrient media and added to a final in-well concentration of 1× (i.e., 20 µl into each well). The xCELLigence system recorded cell index (CI) readings hourly for six days post treatment. GraphPad Prism 6.02 was used for cubic or quadratic non-linear best fit regression (intercept constrained to 1) with least squares fit with comparisons between treatments and TRX controls performed with extra sum of squares *F* test with *P* values of 0.05 and *P* = 0.001 deemed significant and highly significant, respectively.

## 2.6. *Ov-grn-1* gene and double-strand RNAs (dsRNAs) synthesis

The fragment of *Ov-grn-1* of 285 bp (spanning nt no. 49-333, GenBank accession FJ436341) was amplified by PCR from a cDNA library assembled from adult flukes (Laha et al., 2007). The target locus was amplified using specific primers flanked with T7 RNA polymerase promoter sequence (indicated in bold and italicized font) at the 5' ends; *Ov*-dsRNA-T7-Gra-F, 5'-***TAATACGACTCACTATAGGGGTGTTGACGGTGATTTAC***-3' as forward primer and *Ov* dsRNA-T7-Gra-R, 5'-***TAATACGACTCACTATAGGGCTTTCGAGCGTTGAGCATAA***-3') as reverse primer. PCR reactions were carried out as follows: 100 ng of *O. viverrini* cDNA library as template, 0.2 mM dNTP, 1.5 mM MgCl<sub>2</sub> performed with 1 unit *Taq* polymerase (Invitrogen, Germany) with 35 cycles of denaturation at 95°C for 30 sec, annealing at 55°C for 30 sec, extension at 72°C for 45 sec and a final extension at 72°C for 10 min. PCR products were

identified by agarose gel electrophoresis and purified by gel extraction kit (Fermentas, EU). PCR products were ligated into the pGEM-T Easy vector (Promega, USA), after which *Escherichia coli* JM109 competent cells (Promega) were transformed with the ligation products. Recombinant clones were screened on ampicillin with blue/white selection. White colonies were grown in LB, and positive inserts identified by PCR using primers corresponding to the multiple cloning site promoter sequences, T7 and SP6. The extracted plasmids were subjected to sequencing using the BigDye terminator method (1<sup>st</sup> BASE, Singapore).

To synthesize *Ov-grn-1* double stranded RNA (dsRNA), amplicons were generated by PCR from the pGEM-T plasmid clone of *Ov-grn-1* (above). The PCR conditions were 35 cycles of denaturation at 95°C for 30 sec, annealing at 55°C for 30 sec, extension at 72°C for 45 sec and a final extension at 72°C for 10 min. A 285 bp fragment of *Ov-grn-1* (as above) was generated by *in vitro* transcription using specific primers tailed with the T7 RNA polymerase promoter sequence *Ov*-dsRNA-T7-Gra-F and *Ov*-dsRNA-T7-Gra-R (described above). An irrelevant negative control firefly *luciferase* (*Luc*) dsRNA derived from pGL3 was also produced (Promega, USA). *Luc* dsRNA was amplified using primers ds-LUC\_T7-F5' -**TAATACGACTCACTATAGGGT**GCGCCCGCAACGACATTTA and ds-LUC\_T7-R5' -**TAATACGACTCACTATAGGGG**CAACCGCTTCCCCGACTTCCTTA (Rinaldi et al., 2008). The PCR products were *in vitro* single transcribed to produce dsRNAs and purified using the Megascript RNAi kit (Ambion, USA) accorded to the manufacturer's instructions. Integrities of the dsRNAs were assessed on a 1.5% agarose gel and concentrations determined by spectrophotometer (NanoVue, GE Healthcare, USA).

### 2.7. Delivery of *Ov-grn-1* dsRNA into *O. viverrini* adult flukes

Adult stage *O. viverrini* flukes from hamsters were washed several times with sterile normal saline and then washed five times in DMEM (Gibco, USA) containing 2× antibiotics. Flukes were incubated for 1 hour at 37°C in 5% CO<sub>2</sub> atmosphere with DMEM containing 2× antibiotics. The flukes were resuspended in 100 µl of DMEM plus 1x antibiotic and 50 µg of *Ov-grn-1* dsRNA in 4 mm gap cuvettes (Bio-Rad, Hercules, CA, USA) and subjected to a single pulse of square wave electroporation at 125 V for 20 milliseconds (Electroporator Gene Pulser Xcell, Bio-Rad). The parasites were soaked with 50 µg of *Ov-grn-1* dsRNA in 10 ml of 1× DMEM for two days and maintained at 37°C and 5% CO<sub>2</sub> in air before downstream processing.

### 2.8. RNA extraction and quantitative real time-PCR

To determine RNA expression levels, *Ov-grn-1* dsRNA treated worms ( $n = 30$ ) were cultured in RPMI-1640 supplemented with 1x antibiotic and antimycotic, and single worms in triplicate were harvested at days 1, 2, 3, 5 and 7 to evaluate the endogenous expression of *Ov grn-1* mRNA. Flukes that were not exposed to dsRNA but were electroporated in media served as mock controls, and worms exposed to *Luc* dsRNA were used as negative, irrelevant controls. Total RNA of flukes was extracted with TRIZOL (Invitrogen, USA) following the manufacturer's instructions, and contaminating genomic DNA was removed by treatment with DNase I (Thermo-scientific, EU). Concentrations of RNA were determined with a spectrophotometer. cDNAs were synthesized from 1 µg of adult RNA

using a cDNA synthesis kit (Fermentas). *Ov-grn-1* cDNA was amplified using specific primers as follows: forward primer, *Ov-GRN-EXF*: 5'-GGGATCGGTTAGTCTAATCTCC-3', and reverse primer, *Ov-GRN EXR*: 5'-GATCATGGGGGTTCACTGTC) (spanning *Ov-grn-1* coding DNA position 6-365) amplifying a 359 bp product which is larger than the dsRNA used for electroporation and therefore cannot be amplified from exogenous dsRNA. The endogenous actin gene (GenBank AY005475) was used as a housekeeping control (Piratae et al., 2012). Real time PCR was carried out using an ABI7500 thermal cycler and the SYBR Green assay. PCR reactions consisted of 12.5 µl of SYBR Green Master Mix (TAKARA Perfect Real-time Kit), 0.5 µl (10 mM) each of forward and reverse primers, 0.5 µl of reference Dye (ROX), 1 µl (equivalent to 50 ng of total RNA) of first-stand cDNA and water to a final volume of 25 µl. PCR cycling conditions consisted of initiation with pre-heat for one cycle at 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 30 sec, annealing at 55°C for 30 sec, extension at 72°C for 45 sec, and a final extension at 72°C for 10 min. The endogenous *Ov-grn-1* mRNA levels were normalized with actin mRNA. Data is presented as the unit value of  $2^{-Ct}$  where  $Ct = Ct(\text{treated worms}) - Ct(\text{non-treated worms})$ ;  $Ct$  of each group =  $Ct_{\text{grn 1,2,3}} - Ct_{\text{actin(average)}}$ . In addition, RT PCR products amplified from total RNA of adult flukes were run on 1.5% agarose gels in order to visually assess the integrity of the bands.

## 2.9. Viability of parasites

To determine the viability of parasites during *in vitro* culture, twenty worms treated with *Ov-grn-1* dsRNA were cultured in DMEM containing 1x antibiotic; media were changed every two days. Viability of flukes was determined on day 5 by observing movement of oral or ventral suckers using light microscopy in the presence of the vital dye, Trypan blue at 0.1% in PBS for 10 min at 37°C, 5% CO<sub>2</sub>. Flukes were scored as dead if the worm stained blue, or as alive if not stained or stained weakly with Trypan blue and the oral or ventral suckers was still moving (alive), or dead, if no movement was apparent during observation for 10 min duration (Gold, 1997, Rinaldi et al., 2012). Worm survival among treatment groups was compared using independent *t*-tests.

## 2.10. Cell proliferation assay using a non-contact co-culture technique

To evaluate the effect on cell proliferation of suppressing *Ov-grn-1*, viable *O. viverrini* adult flukes that had been electroporated once and soaked with *Ov-grn-1* dsRNAs for 24 hours and cultured in culture media for another day. Flukes were then co-cultured with either H-69 or KKKU-M214 cells using 24-well Transwell plates with a 4 µm pore size membrane separating the upper and lower chambers (Corning, USA). Briefly, 10,000 of either H-69 or KKKU-M214 cells were seeded into the lower chamber of the Transwell plate and cultured for 24 h with complete medium. Complete medium was removed and replaced with incomplete medium, which consisted of complete medium diluted to 3:20 in DMEM/F12 for H-69, and Ham's F-12 supplemented with 1% FBS for KKKU-M214 for overnight and culture medium was renewed with incomplete medium prior to the next experiment. Five active and viable *O. viverrini* adult flukes that had been exposed to *Ov-grn-1* dsRNAs were transferred to the upper chamber of each well. In addition, five adult flukes that had been electroporated/soaked with no dsRNAs were used as a mock control. Wells without flukes served as a negative control. Four replicates of treatments were conducted. The fluke ES but



not the fluke itself could reach the lower chamber, which was separated from the upper chamber by a membrane a pore size of 4  $\mu\text{m}$  diameter. The number of cells in each well was determined at days 1, 2 and 3 using the WST-1 cell proliferation reagent (Roche, Germany), where 10  $\mu\text{l}$  of WST-1 was added to cells at 37°C for up to 30 min for KKU M214 and 2 h for H-69 cells. Absorbance at 450 nm was determined and cell number calculated from a standard curve (following the manufacturer's instructions) before converting into relative growth compared to the negative control. Independent *t*-tests were used to compare treatment with *Ov-grn-1* dsRNA versus the mock control.

### 2.11. Statistical analysis

Mean and standard deviation were calculated using SPSS for windows version 21 or GraphPad Prism software; ANOVA and Student's *t*-test were used to compare groups. *P* 0.05 was considered to be statistically significant.

## 3. Results

### 3.1. Fluke proteins stimulate hyper-proliferation of human cholangiocytes

We compared the effect of *Ov-GRN-1* in stimulating human cholangiocytes (H69s) using recombinant *Ov-GRN-1*, in comparison with a soluble lysate of worms and with ES of *O. viverrini*, using real time cell growth analysis using the xCELLigence system (Figure 1). All four treatments induced cellular proliferation, when compared with controls (PBS or TRX protein) ( $F_{(DFn, DFd)} = 487.5-5253_{(2,1478)}$ ). Cellular growth was monitored for up to 140 hours after treatment, but only up until 90 hours was used for comparisons since the low nutrient media causes control cells numbers to decline. The two controls, PBS vehicle control and the expression matched bacterial TRX, showed similar growth rate curves. It is noted that three of the treatments showed similar profiles, 12 nM *Ov-GRN-1*, 14  $\mu\text{g/ml}$  ES of *O. viverrini* and lysate of worms (SAE), climbed above controls after about one day and reached 27-38% over controls at 90 h. These comparable rates of induction of proliferation allowed approximation that the proportion of *Ov-GRN-1* to represent ~0.8% of the total protein in ES. This assumes that recombinant *Ov-GRN-1* was fully active and that are no other factors from the flukes influenced cell growth-as shown previously by Smout *et al.* (Smout et al., 2009). The lower dose treatment of 3 nM *Ov-GRN-1* also significantly induced growth, compared to control wells, but at a far lower rate of 13% at 90 h ( $F_{(DFn, DFd)} = 487.5_{(2,1478)}$ ).

### 3.2. Suppression of *Ov-grn-1* expression in *Opisthorchis viverrini* by RNAi

In order to investigate the role of *Ov-grn-1* by suppressing its expression via RNAi, we subjected adult flukes to square wave electroporation of *Ov-grn-1* or *Luc* dsRNA (or media alone) and then, in addition, soaked the worms for two days in dsRNA. Total RNA was extracted from the flukes and used as template for quantitative RT-PCR. Potent knockdown of *Ov-grn-1* resulted in flukes treated with *Ov-grn-1* dsRNA compared to controls (Figure 2). Significant knockdown of *Ov-grn-1* gene expression compared to mock controls (*P* 0.001) was evident as early as 48 h after electroporation (91.4% reduced expression), which progressively increased to complete knockdown by day 7 (Figure 2). Thereafter, the majority of the flukes electroporated with *Ov-grn-1* dsRNA were dead; and accordingly

transcript levels were only considered for the first seven days of culture (below). A reduction in the expression of *Ov-grn-1* expression in flukes that were electroporated in *Luc* dsRNA (Figure 2) was not seen. Moreover, differences in expression of the *actin* gene among the groups were not apparent (not shown). RT-PCR products amplified from total RNA of adult that were analyzed on 1.5% agarose gel and showed less intensity corresponding to knockdown level compared to actin which were not different (Figure 2). These findings confirmed the experimental RNAi silencing of *Ov-grn-1* at the transcript level.

### 3.3. Suppression of *Ov-grn-1* mRNA hastened death of worms

To determine the effect of silencing the expression of *Ov-grn-1* on viability of the flukes, we determined viability rates by observing motility and death by Trypan blue exclusion. Viability decreased significantly in *Ov-grn-1* dsRNA-treated worms compared to the mock control group. More specifically, *Ov-grn-1* dsRNA-treated flukes exhibited significantly decreased (40%) viability when compared to intact, control worms by five days of culture in standard medium (not containing dsRNAs) (Figure 3).

### 3.4. Silencing of *Ov-grn-1* results in reduced ability of *O. viverrini* to drive cell proliferation in Transwell co-culture

To further explore the role of *Ov-GRN-1* in driving proliferation of human host cells, *Ov-grn-1* knocked-down worms were co-cultured with cholangiocytes (H-69) and a line of CCA cells (KKU-M214). Compared to electroporation mock control parasites, *Ov-grn-1*-suppressed parasites induced far less cell proliferation of H-69 ( $P = 0.001$ ) and KKU-M214 ( $P = 0.001$ ) after as brief a period as 24 h in culture (Figure 4A and 4B). After three days of cell culture, highly significant inhibition of proliferation continued ( $P = 0.001$ ).

## 4. Discussion

The mechanisms by which infection with *O. viverrini* results in liver disease and chronic infection can ultimately cause CCA are undoubtedly complex, involving multi-factorial mechanisms (Plieskatt et al., 2013, Sripa et al., 2012). Chronic irritation caused by *O. viverrini* induces inflammation of the bile ducts, resulting in hyperplasia of exposed biliary epithelial cells. The induction of cell proliferation is an important step in the genesis of cancer because hyperplastic cells are vulnerable to a carcinogen that can easily induce DNA damage during mitosis and proliferation (Watanapa and Williamson, 1993, Williamson and Rainey, 1984). The mechanisms involved in these phenomena are multifactorial, and may include 1) mechanical, where direct contact of parasites with the bile duct epithelium results in constant abrasion and irritation, and 2) direct and varied effects of ES from the flukes (Sripa et al., 2007) stimuli, among others (Porta et al., 2011). ES from *O. viverrini* can induce proliferation of fibroblasts (Thuwajit et al., 2004) as well as in KKU-100 human cholangiocarcinoma cells (Smout et al., 2009). ES includes a complex catalogue of proteins that have been associated with cancers, particularly the potent growth factor *Ov-GRN-1* (Mulvenna et al., 2010).



Human granulin is expressed as pro-granulin, PGRN, and is a secreted glycoprotein comprised of seven tandem repeats of a 12-cysteine module called granulin A-G or epithelin domains. It is sensitive to hydrolysis by elastase, which liberates peptides of 6 kDa corresponding to individual granulin modules that maintain diverse biological activity (Bateman and Bennett, 1998, Tolkmachev et al., 2008). In addition to the granulin units initiating signal cascades, intact PGRN has key biological activities, including regulation of early embryogenesis, repair of adult tissues and modulation of inflammation. PGRN is involved in multiple steps in the tumor progression cascade, including cellular proliferation, tissue repair, and tumorigenesis (He and Bateman, 2003). For example, treatment of CCA cells with recombinant PGRN results in increased cell proliferation *in vitro*, and suppression of PGRN expression in CCA cells decreases the expression of proliferating cellular nuclear antigen, a marker of proliferative capacity, and retards tumor growth *in vivo* (Frampton et al., 2012). Moreover, PGRN promotes migration of 5637 bladder cancer cells and stimulates wound closure and invasion (Monami et al., 2006). Nonetheless, the signaling cascade is not fully understood since either or both of PGRN or the individual granulin A-G units may be responsible for initiating proliferation.

Earlier findings revealed that *Ov*-GRN-1 stimulates proliferation of murine fibroblasts, and proliferation is inhibited by the MAPK kinase inhibitor, U0126 (Smout et al., 2009). Antibodies raised to recombinant *Ov*-GRN-1 inhibit the ability of ES to induce proliferation of murine fibroblasts and a human CCA cell line *in vitro*, indicating that *Ov*-GRN-1 is the major growth factor present in *O. viverrini* ES products (Smout et al., 2009). In the present study, we silenced the expression of the *Ov-grn-1* gene in adult flukes using RNA interference, and noted a suppression of mitogenicity in the ES products of the fluke. An intriguing finding was the increased lethality that follows silencing of *Ov-grn-1*. This implies that *Ov*-GRN-1 acts as a growth factor for both host cells and the fluke itself. Indeed, to our knowledge, this is the first report describing the silencing of a growth factor gene in a parasitic helminth. The ubiquitous expression of *Ov*-GRN-1 in organs and tissues of adult *O. viverrini* (Smout et al., 2009) supports the notion that this fluke mitogen functions as an essential, endogenous growth factor for *O. viverrini*. It is not unexpected that *Ov*-GRN-1 functions as a growth factor for both the liver fluke and its host cells since granulins evolved in all branches of the animal kingdom and are known to promote proliferation of different cell types from phylogenetically distant taxa (Hanington et al., 2008). Future studies will explore the effects of introducing *Ov-grn-1* dsRNA-treated metacercariae (the infectious stage to mammals) to hamsters to assess survival *in vivo*.

In terms of infiltration of dsRNAs throughout fluke tissues during the RNAi process, notably, electroporation with as little as 50 µg of dsRNA per 100 µl of media followed by soaking in 50 µg/10 ml for two days was sufficient to see significant knock down of *Ov-grn-1* in adult flukes, and resulted in death of some flukes by five days of culture. Andrew *et al* (1998) reported that only a few molecules of injected double-stranded RNA were required per affected cell, arguing against stoichiometric interference with endogenous mRNA and suggesting that there could be a catalytic or amplification component in the interference process (Fire et al., 1998). Previously, electroporation of Cy3-siRNA into adult *O. viverrini* revealed the location of the reporter siRNA throughout the parenchyma of transduced

worms, with accumulation in the gut (Sripa et al., 2011). Furthermore, *Ov*-GRN-1 was detected in fluke gut tissue and ES products, as well as on the surface of biliary epithelial cells of hamsters that were experimentally infected with *O. viverrini* (Smout et al., 2009), underscoring extracellular roles for the protein at the host-parasite interface. Taken together, we suggest that dsRNAs introduced into *O. viverrini* adults enter into apertures on the body of the fluke including the tegument, genital pore and mouth from where they pass through the gut. Presumably the affected cells amplify the component in the interference process, interfering with target gene expression.

In the human liver, differentiated cholangiocytes are mitotically dormant (Priester et al., 2010). Cholangiocyte proliferation may include some combination of proliferation of pre existing ductules, progenitor cell activation, and appearance of intermediate hepatocytes (Priester et al., 2010). Proliferation of cholangiocytes induced by the fluke infection may serve to compensate for cells damaged by the fluke and maintain secretory function (Leite and Nathanson, 2005). Therefore, inhibiting the activity of *Ov*-GRN-1 may decrease excess cell proliferation and potentially inhibit the development of biliary fibrosis or malignancy (Ho et al., 2008, Smout et al., 2009). Hence, *Ov*-GRN-1 may be plausible target of a potential anti-parasitic and/or anti-pathogenic vaccine to control the opisthorchiasis and opisthorchiasis-induced cholangiocarcinoma.

## Acknowledgements

This work was supported by The Higher Education Research Promotion and National Research University Project of Thailand, Office of the Higher Education Commission, through the Health Cluster (SHeP-GMS), Khon Kaen University to AP and TL, a Tropical Medicine Research Center award number P50AI098639 (TL, BS) from the National Institute of Allergy and Infectious Diseases (NIAID), and award number R01CA CA164719 (AL, PJB, TL) from the National Cancer Institute (NCI), US National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, the NCI or the NIH.

## References

- Bateman A, Bennett HP. Granulins: the structure and function of an emerging family of growth factors. *J Endocrinol.* 1998; 158:145–151. [PubMed: 9771457]
- Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Coglianò V. A review of human carcinogens--Part B: biological agents. *Lancet Oncol.* 2009; 10:321–322. [PubMed: 19350698]
- de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *Lancet Oncol.* 2012; 13:607–615. [PubMed: 22575588]
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature.* 1998; 391:806–811. [PubMed: 9486653]
- Frampton G, Invernizzi P, Bernuzzi F, Pae HY, Quinn M, Horvat D, Galindo C, Huang L, McMillin M, Cooper B. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. *Gut.* 2012; 61:268–277. [PubMed: 22068162]
- Gold D. Assessment of the viability of *Schistosoma mansoni* schistosomula by comparative uptake of various vital dyes. *Parasitol Res.* 1997; 83:163–169. [PubMed: 9039699]
- Grubman SA, Perrone RD, Lee DW, Murray SL, Rogers LC, Wolkoff LI, Mulberg AE, Cherington V, Jefferson DM. Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines. *Am J Physiol.* 1994; 266:G1060–1070. [PubMed: 8023938]

- Hanington PC, Brennan LJ, Belosevic M, Andrew Keddie B. Molecular and functional characterization of granulin-like molecules of insects. *Insect Biochem Mol Biol*. 2008; 38:596–603. [PubMed: 18405836]
- He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. *J Mol Med (Berl)*. 2003; 81:600–612. [PubMed: 12928786]
- Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY, Fan ST. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. *Hepatology*. 2008; 47:1524–1532. [PubMed: 18393387]
- IARC. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 2012; 100:1–441.
- Ke N, Wang X, Xu X, Abassi YA. The xCELLigence system for real-time and label-free monitoring of cell viability. *Methods Mol Biol*. 2011; 740:33–43. [PubMed: 21468966]
- Knox DP. Developments in RNA interference and genetic transformation to define gene function in parasitic helminths. *Parasitology*. 2012; 139:557–559. [PubMed: 22459432]
- Laha T, Pinlaor P, Mulvenna J, Sripa B, Sripa M, Smout MJ, Gasser RB, Brindley PJ, Loukas A. Gene discovery for the carcinogenic human liver fluke, *Opisthorchis viverrini*. *BMC Genomics*. 2007; 8:189. [PubMed: 17587442]
- Leite, MF.; Nathanson, MH. Signaling Pathways in Biliary Epithelial Cells. *Signaling Pathways in Liver Diseases*; Springer: 2005. p. 17-26.
- Mairiang E, Laha T, Bethony JM, Thinkhamrop B, Kaewkes S, Sithithaworn P, Tesana S, Loukas A, Brindley PJ, Sripa B. Ultrasonography assessment of hepatobiliary abnormalities in 3359 subjects with *Opisthorchis viverrini* infection in endemic areas of Thailand. *Parasitol Int*. 2012; 61:208–211. [PubMed: 21771664]
- Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. *J Hepatol*. 2006; 45:856–867. [PubMed: 17030071]
- Matsumura T, Takesue M, Westerman KA, Okitsu T, Sakaguchi M, Fukazawa T, Totsugawa T, Noguchi H, Yamamoto S, Stolz DB, Tanaka N, Leboulch P, Kobayashi N. Establishment of an immortalized human-liver endothelial cell line with SV40T and hTERT. *Transplantation*. 2004; 77:1357–1365. [PubMed: 15167590]
- Monami G, Gonzalez EM, Hellman M, Gomella LG, Baffa R, Iozzo RV, Morrione A. Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. *Cancer Res*. 2006; 66:7103–7110. [PubMed: 16849556]
- Mulvenna J, Sripa B, Brindley PJ, Gorman J, Jones MK, Colgrave ML, Jones A, Nawaratna S, Laha T, Suttiyapra S, Smout MJ, Loukas A. The secreted and surface proteomes of the adult stage of the carcinogenic human liver fluke *Opisthorchis viverrini*. *Proteomics*. 2010; 10:1063–1078. [PubMed: 20049860]
- Park MY, Park YS, Nam JH. RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: its application as a therapeutic agent. *Int J Oncol*. 2011; 39:853–861. [PubMed: 21701774]
- Piratae S, Tesana S, Jones MK, Brindley PJ, Loukas A, Lovas E, Eursitthichai V, Sripa B, Thanasuwan S, Laha T. Molecular characterization of a tetraspanin from the human liver fluke, *Opisthorchis viverrini*. *PLoS Negl Trop Dis*. 2012; 6:e1939. [PubMed: 23236532]
- Plieskatt JL, Deenonpoe R, Mulvenna JP, Krause L, Sripa B, Bethony JM, Brindley PJ. Infection with the carcinogenic liver fluke *Opisthorchis viverrini* modifies intestinal and biliary microbiome. *FASEB J*. 2013; 27:4572–4584. [PubMed: 23925654]
- Porta C, Riboldi E, Sica A. Mechanisms linking pathogens-associated inflammation and cancer. *Cancer Lett*. 2011; 305:250–262. [PubMed: 21093147]
- Priester S, Wise C, Glaser SS. Involvement of cholangiocyte proliferation in biliary fibrosis. *World journal of gastrointestinal pathophysiology*. 2010; 1:30. [PubMed: 21607140]
- Razumilava N, Gores GJ. Cholangiocarcinoma. *Lancet*. 2014; 383:2168–2179. [PubMed: 24581682]
- Reid LM, Jefferson DM. Culturing hepatocytes and other differentiated cells. *Hepatology*. 1984; 4:548–559. [PubMed: 6373552]


- Rinaldi G, Morales ME, Cancela M, Castillo E, Brindley PJ, Tort JF. Development of functional genomic tools in trematodes: RNA interference and luciferase reporter gene activity in *Fasciola hepatica*. *PLoS Negl Trop Dis*. 2008; 2:e260. [PubMed: 18612418]
- Rinaldi G, Suttiprapa S, Tort JF, Folley AE, Skinner DE, Brindley PJ. An antibiotic selection marker for schistosome transgenesis. *Int J Parasitol*. 2012; 42:123–130. [PubMed: 22155152]
- Shuey DJ, McCallus DE, Giordano T. RNAi: gene-silencing in therapeutic intervention. *Drug Discov Today*. 2002; 7:1040–1046. [PubMed: 12546893]
- Sithithaworn P, Andrews RH, Nguyen VD, Wongsaroj T, Sinuon M, Odermatt P, Nawa Y, Liang S, Brindley PJ, Sripan B. The current status of opisthorchiasis and clonorchiasis in the Mekong Basin. *Parasitol Int*. 2012; 61:10–16. [PubMed: 21893213]
- Sithithaworn P, Pipitgool V, Srisawangwong T, Elkins DB, Haswell-Elkins MR. Seasonal variation of *Opisthorchis viverrini* infection in cyprinoid fish in north-east Thailand: implications for parasite control and food safety. *Bull World Health Organ*. 1997; 75:125–131. [PubMed: 9185364]
- Smout MJ, Laha T, Mulvenna J, Sripan B, Suttiprapa S, Jones A, Brindley PJ, Loukas A. A granulin-like growth factor secreted by the carcinogenic liver fluke, *Opisthorchis viverrini*, promotes proliferation of host cells. *PLoS Pathog*. 2009; 5:e1000611. [PubMed: 19816559]
- Smout MJ, Mulvenna JP, Jones MK, Loukas A. Expression, refolding and purification of Ov-GRN-1, a granulin-like growth factor from the carcinogenic liver fluke, that causes proliferation of mammalian host cells. *Protein Expression and Purification*. 2011; 79:263–270. [PubMed: 21757010]
- Smout MJ, Sripan B, Laha T, Mulvenna J, Gasser RB, Young ND, Bethony JM, Brindley PJ, Loukas A. Infection with the carcinogenic human liver fluke, *Opisthorchis viverrini*. *Mol Biosyst*. 2011; 7:1367–1375. [PubMed: 21311794]
- Sripan B. Global burden of food-borne trematodiasis. *Lancet Infect Dis*. 2012; 12:171–172. [PubMed: 22108755]
- Sripan B, Bethony JM, Sithithaworn P, Kaewkes S, Mairiang E, Loukas A, Mulvenna J, Laha T, Hotez PJ, Brindley PJ. Opisthorchiasis and *Opisthorchis*-associated cholangiocarcinoma in Thailand and Laos. *Acta Trop*. 2011; 120(Suppl 1):S158–168. [PubMed: 20655862]
- Sripan B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, Bethony JM, Loukas A. The tumorigenic liver fluke *Opisthorchis viverrini*--multiple pathways to cancer. *Trends Parasitol*. 2012; 28:395–407. [PubMed: 22947297]
- Sripan B, Kaewkes S. Relationship between parasite-specific antibody responses and intensity of *Opisthorchis viverrini* infection in hamsters. *Parasite Immunology*. 2000; 22:139–145. [PubMed: 10672195]
- Sripan B, Kaewkes S. Gall bladder and extrahepatic bile duct changes in *Opisthorchis viverrini*-infected hamsters. *Acta Trop*. 2002; 83:29–36. [PubMed: 12062790]
- Sripan B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, Pairojkul C, Bhudhisawasdi V, Tesana S, Thinkamrop B, Bethony JM, Loukas A, Brindley PJ. Liver fluke induces cholangiocarcinoma. *PLoS Med*. 2007; 4:e201. [PubMed: 17622191]
- Sripan B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripan C, Miwa M. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). *World J Gastroenterol*. 2005; 11:3392–3397. [PubMed: 15948244]
- Sripan B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. *Curr Opin Gastroenterol*. 2008; 24:349–356. [PubMed: 18408464]
- Sripan J, Pinlaor P, Brindley PJ, Sripan B, Kaewkes S, Robinson MW, Young ND, Gasser RB, Loukas A, Laha T. RNA interference targeting cathepsin B of the carcinogenic liver fluke, *Opisthorchis viverrini*. *Parasitol Int*. 2011; 60:283–288. [PubMed: 21565281]
- Thanasuwan S, Piratae S, Brindley PJ, Loukas A, Kaewkes S, Laha T. Suppression of aquaporin, a mediator of water channel control in the carcinogenic liver fluke, *Opisthorchis viverrini*. *Parasit Vectors*. 2014; 7:224. [PubMed: 24885060]
- Thuwajit C, Thuwajit P, Kaewkes S, Sripan B, Uchida K, Miwa M, Wongkham S. Increased cell proliferation of mouse fibroblast NIH-3T3 in vitro induced by excretory/secretory product (s) from *Opisthorchis viverrini*. *Parasitology*. 2004; 129:455–464. [PubMed: 15521634]

- Tolkatchev D, Malik S, Vinogradova A, Wang P, Chen Z, Xu P, Bennett HP, Bateman A, Ni F. Structure dissection of human progranulin identifies well-folded granulin/epithelin modules with unique functional activities. *Protein Sci.* 2008; 17:711–724. [PubMed: 18359860]
- Watanapa P, Williamson RC. Experimental pancreatic hyperplasia and neoplasia: effects of dietary and surgical manipulation. *Br J Cancer.* 1993; 67:877–884. [PubMed: 8494719]
- Williamson RC, Rainey JB. The relationship between intestinal hyperplasia and carcinogenesis. *Scand J Gastroenterol Suppl.* 1984; 104:57–76. [PubMed: 6597550]

### HIGHLIGHTS


- >Granulin of *Opisthorchis viverrini* is susceptible to experimental RNA interference
- >Suppression of granulin reduced ability of ES products to drive cell proliferation
- >Knock down of granulin hastened death of cultured liver flukes






**Figure 1. Proteins from *Opisthorchis viverrini* stimulate the proliferation of human cholangiocytes *in vitro***

Normalized Cell Index is the output from the xCELLigence instrument. *Ov*-GRN-1 is produced in *E. coli* expressed and refolded into an active growth factor. The lysate of *O. viverrini* represents a soluble extract of adult *Opisthorchis viverrini* worms. *Ov*ES (excreted/secreted products) is the supernatant from cultured adult *O. viverrini*. TRX is thioredoxin from *E. coli* and is an expression-matched control for *Ov*-GRN-1. Error bars reveal the standard error of triplicate biological replicates. \*\*\*\* denotes statistical significance at the level of  $P < 0.0001$ .




**Figure 2. Gene-specific silencing of *Ov-grn-1* in *Opisthorchis viverrini* following delivery of dsRNA by square wave electroporation**

Real-time qPCR analysis revealed the transcript levels of *Ov-grn-1* normalized to levels of *Ov-actin* in flukes after electroporation and soaking with *Ov-grn-1* or *luciferase (Luc)* dsRNAs. *Ov-grn-1* transcript levels had decreased significantly by day 1 and were not detectable by day 7. *Ov-grn-1* RT-PCR products amplified from total RNA of adult flukes after electroporation with either *Ov-grn-1* or *Luc* dsRNAs (inset). Data are represented by mean  $\pm$  1 standard deviation; \*\*\* denotes statistical significance at the level of  $P = 0.001$ .



**Figure 3. Survival rate of *Opisthorchis viverrini* after RNAi-based silencing of *Ov-grn-1***  
Twenty adult flukes were cultured for five days. The worms were examined the viability with Trypan blue by light microscopy. Data were represented by mean  $\pm$  1 standard deviation. Significance at the level of  $P = 0.05$  level denoted with \* in a comparison with flukes not exposed to dsRNA but subjected to identical electroporation (mock).



**Figure 4. Proliferation of cholangiocytes repressed after exposure to *Opisthorchis viverrini* subjected to gene knockdown of *Ov-grn-1***

Growth expressed as the ratio of cell numbers per well between treatment and control groups (“no parasites” used as 100% negative control). The effect of specific repression of expression of *Ov-grn-1* on growth of lines of immortalized cholangiocytes (H69 cell line) (panel A) and cholangiocarcinoma cells (KKU-M214 cells) (Panel B) resulted in significantly decreased proliferation compared to controls during cultivation for three days. Findings presented as the means of biological quadruplicates, with the standard deviation shown as bars. Asterisks indicate significant differences between mock control and *Ov-grn-1* dsRNA treatments: \*\* and \*\*\* represent  $P = 0.01$  and  $0.001$ , respectively.